Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy

Niya, Mohammad Hadi Karbalaie; Salman-Tabar, Samira; Bokharaei‐Salim, Farah; Behmanesh, Mehrdad; Keyvani, Hossein

doi:10.1016/j.micpath.2017.01.060

Cited by 11 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nonstructural protein 5B (NS5B) gene and the 5′‐UTR were amplified using RT‐nested PCR as described (with some modification) . After cDNA synthesis, nested PCR was performed in 25 µL of reaction mixture with 1.2 units EX Taq DNA polymerase (TaKaRa Biotechnology [Dalian] Co, Ltd, Shiga, Japan), 2.5 µL 10× Ex Taq buffer (Mg 2+ free), 2 µL MgCl 2 (25 mM), 2 µL dNTPs mixture (25 mM each) and 2.5 µL cDNA was used as a template of the first stage of PCR, and 1.5 µL of the first round PCR product was used as a template for the second stage of PCR.…”

Section: Methodsmentioning

confidence: 99%

Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta‐thalassemia major: Occult HCV infection

Kahyesh‐Esfandiary

Sadigh

Esghaei

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

Beta (β) thalassemia major is a genetic blood disorder with a deficiency in the hemoglobin beta chain, requiring blood transfusion therapy. Multiple blood transfusions increase the risk of transmitting blood-borne infections. The aim of this study is to determine the frequency of hepatitis C virus (HCV) infection in Iranian individuals with β-thalassemia major. A total of 164 patients with β-thalassemia major were recruited for this study. HCV RNA testing was done on plasma and peripheral blood mononuclear cells (PBMCs) from the HCV seropositive samples (with reverse transcriptase-nested polymerase chain reaction [PCR] method using primers from the 5'-untranslated region [UTR]), and all HCV RNA positive samples were genotyped by the restriction fragment length polymorphism assay. For confirmation of the HCV genotyping in PBMCs of occult HCV infection [OCI]-positive patients, the PCR products of two different regions of HCV (5'-UTR and nonstructural protein 5B [NS5B]) were sequenced. Of 164 patients, 29.3% were positive for anti-HCV antibodies, and HCV RNA was detected in the plasma specimens of 13.4% patients and in the PBMC samples of 15.2% participants. The genomic HCV-RNA was detected in PBMC samples in 3 (6.3%) of the total 48 individuals who were HCV seropositive, and plasma HCV-RNA negative (occult HCV infection). The subtypes of HCV in the plasma and PBMC samples of three participants were not identical. This study shows that among this group of Iranian patients with β-thalassemia major, 13.4% had active HCV infection and 6.3% had occult HCV infection as evidenced by HCV RNA detected in PBMC specimens. Therefore, the design of a prospective study that focuses on the diagnosis of OCI can be very valuable and provide more information.

show abstract

Section: Methodsmentioning

confidence: 99%

Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta‐thalassemia major: Occult HCV infection

Kahyesh‐Esfandiary

Sadigh

Esghaei

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…These novel antiviral drugs, despite having considerable advantages over conventional IFN-based therapy, suffer from the resistance-associated mutations, which occur naturally during the replication of the virus and select under the pressure of DAAs. The emergence of HCV resistance-associated variants (RAVs) decreases the susceptibility to DAAs and finally results in treatment failure[ 38 , 44 - 46 ]. Assessment of resistance substitutions at pretreatment baseline in patients candidate for DAA therapy seems to be the best option to optimize first-line therapeutic strategies, to avoid the fitness of resistant variants as the predominant viral population and to prevent DAA failure due to baseline resistant variants.…”

Section: Progresses In the Management Of Hcv Infectionmentioning

confidence: 99%

Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

Taherkhani¹,

Farshadpour²

2017

WJH

View full text Add to dashboard Cite

Today, with the introduction of interferon-free direct-acting antivirals and outstanding progresses in the prevention, diagnosis and treatment of hepatitis C virus (HCV) infection, the elimination of HCV infection seems more achievable. A further challenge is continued transmission of HCV infection in high-risk population specially injecting drug users (IDUs) as the major reservoir of HCV infection. Considering the fact that most of these infections remain undiagnosed, unidentified HCV-infected IDUs are potential sources for the rapid spread of HCV in the community. The continuous increase in the number of IDUs along with the rising prevalence of HCV infection among young IDUs is harbinger of a forthcoming public health dilemma, presenting a serious challenge to control transmission of HCV infection. Even the changes in HCV genotype distribution attributed to injecting drug use confirm this issue. These circumstances create a strong demand for timely diagnosis and proper treatment of HCV-infected patients through risk-based screening to mitigate the risk of HCV transmission in the IDUs community and, consequently, in the society. Meanwhile, raising general awareness of HCV infection, diagnosis and treatment through public education should be the core activity of any harm reduction intervention, as the root cause of failure in control of HCV infection has been lack of awareness among young drug takers. In addition, effective prevention, comprehensive screening programs with a specific focus on high-risk population, accessibility to the new anti-HCV treatment regimens and public education should be considered as the top priorities of any health policy decision to eliminate HCV infection.

show abstract

“…To verify the results obtained from HCV genotyping by RFLP assay, plasma, and PBMC specimens of five patients (10 samples) were randomly selected and amplified using RT‐nested‐PCR method with other primers for 5′‐UTR, and nonstructural protein 5B (NS5B) region of HCV . After cDNA synthesis (described above), the first and second steps of nested‐PCR were carried out in a 25 μL of the mixture reaction with 1.0 unit EX Taq DNA polymerase (TaKaRa Biotechnology [Dalian] Co., Ltd, Shiga, Japan), 2 μL MgCl2 (25 mM), 2.5 μL 10X Ex Taq buffer (Mg2 + free), 2 μL dNTPs Mixture (25 mM each), 15 pmol of each primers included.…”

Section: Methodsmentioning

confidence: 99%

Presence of different hepatitis C virus genotypes in plasma and peripheral blood mononuclear cell samples of Iranian patients with HIV infection

Dehghani‐Dehej

Sarvari

Esghaei

et al. 2018

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Due to the similar routes of transmission, individuals infected with the human immunodeficiency virus (HIV) may become infected with the hepatitis C virus (HCV) simultaneously. The aim of this study was to investigate the frequency of HCV co-infection in Iranian individuals with HIV infection, and to genotype HCV in plasma and PBMC specimens of these patients. From September 2015 to October 2016, a total of 140 Iranian individuals with HIV infection were enrolled in this cross-sectional study. The RNA from plasma and PBMC specimens was extracted, and genomic HCV-RNA was amplified using RT-nested PCR with primers that target 5'-UTR. The HCV genotyping used the RFLP technique. To confirm HCV genotype, 10 randomly selected HCV-positive samples were also submitted for sequencing. The mean age of patients was 35.7 ± 13.5 years (range: 1-66). Out of 140 patients, 62 (44.3 %) were positive for anti-HCV antibodies; among these, viral genomic RNA was detected in 34 (24.3%) and 39 (27.9%) of the plasma and PBMC specimens, respectively. The HCV genotyping showed a similar pattern of subtypes 1a (44% vs 46.2%), 3a (32.4% vs 33.3%), and 1b (17.6% vs 17.9%) in all sera and PBMC samples. It is noteworthy that the HCV genotypes in plasma and PBMC specimens of 6 HCV co-infected patients were not the same. This study reveals that HIV/HCV co-infection is high in Iranian patients (44.3%), especially in people who have high-risk factors (83.9%). Also, HIV/HCV co-infected individuals may have dissimilar HCV genotypes in their plasma and PBMC specimens.

show abstract

Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy

Cited by 11 publications

References 10 publications

Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta‐thalassemia major: Occult HCV infection

Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta‐thalassemia major: Occult HCV infection

Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

Presence of different hepatitis C virus genotypes in plasma and peripheral blood mononuclear cell samples of Iranian patients with HIV infection

Contact Info

Product

Resources

About